Xcout IntelContext Therapeutics Inc. competitors & alternatives
The 12 closest competitors and alternatives to Context Therapeutics Inc. among biotechnology companies — ranked by similarity to what Context Therapeutics Inc. actually does, not by market-cap band.
Subscribe to see Context Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Context Therapeutics Inc.
Context Therapeutics Inc. is a biopharmaceutical company headquartered in Philadelphia, Pennsylvania. It is committed to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibodies.
Context Therapeutics Inc. at a glance
Context Therapeutics Inc. is a biotechnology company headquartered in Philadelphia, United States. It is publicly listed (CNTX) with a market capitalisation of $48.7M. Xcout tracks 29 named people at Context Therapeutics Inc., including Martin Lehr (Chief Executive Officer).
Context Therapeutics Inc. leadership
- Martin LehrChief Executive Officer
- Jennifer Minai-AzaryChief Financial Officer & Treasurer
- Alex C. LevitChief Legal Officer & Corporate Secretary
- Karen ChaginChief Medical Officer
- Alex LevitChief Legal Officer
- Martin A. LehrCo-Founder, President, Chief Executive Officer & Director
23 more named people on record for Context Therapeutics Inc., with roles, board committees and tenure — see the full roster →
Top 12 Context Therapeutics Inc. competitors
Ranked by semantic similarity — how close each company is to Context Therapeutics Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Similar biotechnology company
Carisma Therapeutics is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on discovering and developing engineered macrophage-based immunotherapies.
Similar biotechnology company
Century Therapeutics is an innovative biotechnology company headquartered in Philadelphia, Pennsylvania. Its mission is to develop allogeneic, iPSC-derived NK and T cell therapies that are designed to be more effective, tolerable, and accessible.
Similar biotechnology company
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
Similar biotechnology company
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
Biotech
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Similar biotechnology company
Imvax, Inc. is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing personalized, whole-cell immunotherapies for the treatment of various cancers.
Similar biotechnology company
Third Arc Bio, Inc. is a clinical-stage biotechnology company founded in 2022 and based in Ambler, Pennsylvania, dedicated to developing multifunctional antibodies optimized for best-in-class therapies.
Biotech
Excalipoint Therapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China. The firm is dedicated to developing next-generation T-cell engager (TCE) therapies and unlocking the therapeutic potential of T-cell based treatments.
Biotech
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Biotech
Crossbow Therapeutics is a privately held biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company develops potent antibody therapeutics aimed at expanding treatment options and combating cancer.
Biotech
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Context Therapeutics Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Context Therapeutics Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →